Compare Nuvalent Inc (NUVL) vs Sanofi SA (SNY) Price & Performance

Nuvalent IncTrade

Sanofi SATrade

Price performance (Past 24H)

Key statistics

Nuvalent Inc vs Sanofi SA — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 10.7× Nuvalent Inc's market cap, and Sanofi SA pays a 5.5% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

	NUVL	SNY
Market Cap	$9.81B	$104.83B
Sector	Technology	Health
52-Week High	$123.96	$52.34
52-Week Low	$72.16	$41.33
Enterprise Value	$8.52B	$121.32B
Dividend Yield	—	5.5%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NUVL

Brodsky & Smith investigates fiduciary duty breaches in multiple major merger deals.GlobeNewsWire · 11 hours agoBearish View details →

SNY

Sanofi reshapes Executive Committee to drive its next strategic phase starting September 2026GlobeNewsWire · 10 hours agoNeutral View details →

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.